ANAVEX LIFE SCIENCES CORP. Debt Issuance Costs, Net
ANAVEX LIFE SCIENCES CORP. (AVXL) had Debt Issuance Costs, Net of $151.13 thousand as of 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DeferredFinanceCostsNet · last filed 2019-12-16
- 2019-03-31: Debt Issuance Costs, Net $151.13K.
- 2018-12-31: Debt Issuance Costs, Net $151.13K.
- 2018-09-30: Debt Issuance Costs, Net $101.13K.
- 2018-06-30: Debt Issuance Costs, Net $50.00K.
| Period end | Debt Issuance Costs, Net |
|---|---|
| 2019-03-31 | $151.13K 10-Q · filed 2019-05-09 |
| 2018-12-31 | $151.13K 10-Q · filed 2019-02-07 |
| 2018-09-30 | $101.13K 10-K · filed 2019-12-16 |
| 2018-06-30 | $50.00K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $30.94K 10-Q · filed 2018-05-10 |
| 2014-06-30 | $1.11M 10-Q · filed 2014-08-13 |
| 2014-03-31 | $1.07M 10-Q/A · filed 2014-05-30 |
| 2013-09-30 | $0.00 10-Q · filed 2014-08-13 |
| 2013-06-30 | $1.83K 10-Q · filed 2013-08-14 |
| 2013-03-31 | $0.00 10-Q · filed 2013-05-17 |
| 2012-12-31 | $0.00 10-Q · filed 2013-02-14 |
| 2012-09-30 | $1.22K 10-K · filed 2013-12-30 |
| 2012-06-30 | $2.90K 10-Q · filed 2012-08-17 |
| 2012-03-31 | $9.99K 10-Q · filed 2012-05-15 |
| 2011-09-30 | $55.46K 10-K · filed 2012-12-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |